[Form 4] Ligand Pharmaceuticals Inc. Insider Trading Activity
John W. Kozarich, a director of Ligand Pharmaceuticals Inc. (LGND), reported share dispositions on 09/02/2025 made pursuant to a written Rule 10b5-1 trading plan adopted March 07, 2025. The Form 4 discloses sales executed on that date with weighted-average prices in three ranges: $161.03–$162.02, $162.36–$162.60, and $163.99–$164.50. The filings list disposals associated with those transactions and include a signature by an attorney-in-fact on 09/04/2025. The filer states it will provide, upon request, full breakdowns of shares sold at each price within the disclosed ranges.
John W. Kozarich, membro del consiglio di Ligand Pharmaceuticals Inc. (LGND), ha comunicato cessioni di azioni il 02/09/2025 effettuate in base a un piano di negoziazione scritto ai sensi della regola 10b5-1 adottato il 07/03/2025. Il modulo Form 4 riferisce vendite eseguite in quella data con prezzi medi ponderati suddivisi in tre fasce: $161.03–$162.02, $162.36–$162.60 e $163.99–$164.50. Le dichiarazioni elencano le cessioni correlate a tali operazioni e includono la firma di un procuratore il 04/09/2025. Il dichiarante precisa che, su richiesta, fornirà il dettaglio completo delle azioni vendute per ciascun prezzo all’interno delle fasce indicate.
John W. Kozarich, miembro del consejo de Ligand Pharmaceuticals Inc. (LGND), informó disposiciones de acciones el 02/09/2025 realizadas conforme a un plan de negociación por escrito según la regla 10b5-1 adoptado el 07/03/2025. El Formulario 4 divulga ventas ejecutadas en esa fecha con precios promedio ponderados en tres rangos: $161.03–$162.02, $162.36–$162.60 y $163.99–$164.50. Las presentaciones detallan las disposiciones asociadas a dichas transacciones e incluyen la firma de un apoderado el 04/09/2025. El declarante indica que, a solicitud, proporcionará el desglose completo de las acciones vendidas a cada precio dentro de los rangos publicados.
John W. Kozarich는 Ligand Pharmaceuticals Inc.(LGND)의 이사로서 2025년 9월 2일, 2025년 3월 7일 채택된 서면 Rule 10b5-1 거래계획에 따라 주식 처분을 보고했습니다. Form 4는 해당 날짜에 체결된 매도 거래들을 공시하며 가중평균가격이 세 구간으로 표시되어 있습니다: $161.03–$162.02, $162.36–$162.60, $163.99–$164.50. 제출서류에는 해당 거래와 관련된 처분 내역이 기재되어 있고, 2025년 9월 4일 대리인의 서명이 포함되어 있습니다. 제출인은 요청 시 공개된 구간별 각 가격에서 매도된 주식의 세부 내역을 제공하겠다고 밝혔습니다.
John W. Kozarich, administrateur de Ligand Pharmaceuticals Inc. (LGND), a déclaré des cessions d’actions le 02/09/2025 effectuées en vertu d’un plan de négociation écrit conforme à la règle 10b5‑1 adopté le 07/03/2025. Le formulaire 4 dévoile des ventes exécutées ce jour-là avec des prix moyens pondérés répartis en trois fourchettes : $161.03–$162.02, $162.36–$162.60 et $163.99–$164.50. Les dépôts énumèrent les cessions liées à ces opérations et incluent la signature d’un mandataire en date du 04/09/2025. Le déclarant précise qu’il fournira, sur demande, le détail complet des actions vendues à chaque prix au sein des fourchettes divulguées.
John W. Kozarich, ein Direktor von Ligand Pharmaceuticals Inc. (LGND), meldete am 02.09.2025 Aktienveräußerungen, die im Rahmen eines schriftlichen Rule‑10b5‑1‑Handelsplans vorgenommen wurden, der am 07.03.2025 beschlossen wurde. Das Formular 4 gibt Verkäufe an diesem Datum mit gewichteten Durchschnittspreisen in drei Spannen an: $161.03–$162.02, $162.36–$162.60 und $163.99–$164.50. Die Einreichungen listen die im Zusammenhang mit diesen Transaktionen stehenden Veräußerungen auf und enthalten eine Unterschrift eines Bevollmächtigten vom 04.09.2025. Der Einreicher erklärt, dass er auf Anfrage eine vollständige Aufschlüsselung der in den genannten Spannen zu jedem Preis verkauften Aktien bereitstellen wird.
- Transactions were executed under a documented Rule 10b5-1 trading plan, which can indicate pre-scheduled, non-opportunistic trades
- Filing provides weighted-average price ranges and commits to supplying per-price sale breakdowns on request, supporting transparency
- Director disposed of shares on 09/02/2025, which may reduce insider ownership stake
- Form 4 does not disclose exact number of shares sold at each specific price within the provided ranges (only weighted-average ranges are given)
Insights
TL;DR: Routine insider sales under a 10b5-1 plan; no new company disclosures or material corporate events reported.
The Form 4 documents that Director John W. Kozarich executed share sales on 09/02/2025 pursuant to a written trading plan adopted 03/07/2025 in accordance with Rule 10b5-1. The filing provides weighted-average price ranges for the transactions and commits to disclose per-price quantities on request. From an investor-disclosure perspective, this is a standard Section 16 filing that notifies the market of director disposals but does not disclose company operational or financial changes.
TL;DR: Sales executed under an established plan limit signaling; filing meets standard disclosure requirements.
The report explicitly indicates the trades occurred pursuant to a pre-established 10b5-1 plan, which typically reduces concerns about opportunistic trading tied to undisclosed information. The Form 4 includes the weighted-average price information and offers full per-price breakdowns upon request, satisfying transparency expectations for insider transaction reporting. No amendments, unusual transaction codes, or additional beneficial ownership changes are reported beyond the disposals.
John W. Kozarich, membro del consiglio di Ligand Pharmaceuticals Inc. (LGND), ha comunicato cessioni di azioni il 02/09/2025 effettuate in base a un piano di negoziazione scritto ai sensi della regola 10b5-1 adottato il 07/03/2025. Il modulo Form 4 riferisce vendite eseguite in quella data con prezzi medi ponderati suddivisi in tre fasce: $161.03–$162.02, $162.36–$162.60 e $163.99–$164.50. Le dichiarazioni elencano le cessioni correlate a tali operazioni e includono la firma di un procuratore il 04/09/2025. Il dichiarante precisa che, su richiesta, fornirà il dettaglio completo delle azioni vendute per ciascun prezzo all’interno delle fasce indicate.
John W. Kozarich, miembro del consejo de Ligand Pharmaceuticals Inc. (LGND), informó disposiciones de acciones el 02/09/2025 realizadas conforme a un plan de negociación por escrito según la regla 10b5-1 adoptado el 07/03/2025. El Formulario 4 divulga ventas ejecutadas en esa fecha con precios promedio ponderados en tres rangos: $161.03–$162.02, $162.36–$162.60 y $163.99–$164.50. Las presentaciones detallan las disposiciones asociadas a dichas transacciones e incluyen la firma de un apoderado el 04/09/2025. El declarante indica que, a solicitud, proporcionará el desglose completo de las acciones vendidas a cada precio dentro de los rangos publicados.
John W. Kozarich는 Ligand Pharmaceuticals Inc.(LGND)의 이사로서 2025년 9월 2일, 2025년 3월 7일 채택된 서면 Rule 10b5-1 거래계획에 따라 주식 처분을 보고했습니다. Form 4는 해당 날짜에 체결된 매도 거래들을 공시하며 가중평균가격이 세 구간으로 표시되어 있습니다: $161.03–$162.02, $162.36–$162.60, $163.99–$164.50. 제출서류에는 해당 거래와 관련된 처분 내역이 기재되어 있고, 2025년 9월 4일 대리인의 서명이 포함되어 있습니다. 제출인은 요청 시 공개된 구간별 각 가격에서 매도된 주식의 세부 내역을 제공하겠다고 밝혔습니다.
John W. Kozarich, administrateur de Ligand Pharmaceuticals Inc. (LGND), a déclaré des cessions d’actions le 02/09/2025 effectuées en vertu d’un plan de négociation écrit conforme à la règle 10b5‑1 adopté le 07/03/2025. Le formulaire 4 dévoile des ventes exécutées ce jour-là avec des prix moyens pondérés répartis en trois fourchettes : $161.03–$162.02, $162.36–$162.60 et $163.99–$164.50. Les dépôts énumèrent les cessions liées à ces opérations et incluent la signature d’un mandataire en date du 04/09/2025. Le déclarant précise qu’il fournira, sur demande, le détail complet des actions vendues à chaque prix au sein des fourchettes divulguées.
John W. Kozarich, ein Direktor von Ligand Pharmaceuticals Inc. (LGND), meldete am 02.09.2025 Aktienveräußerungen, die im Rahmen eines schriftlichen Rule‑10b5‑1‑Handelsplans vorgenommen wurden, der am 07.03.2025 beschlossen wurde. Das Formular 4 gibt Verkäufe an diesem Datum mit gewichteten Durchschnittspreisen in drei Spannen an: $161.03–$162.02, $162.36–$162.60 und $163.99–$164.50. Die Einreichungen listen die im Zusammenhang mit diesen Transaktionen stehenden Veräußerungen auf und enthalten eine Unterschrift eines Bevollmächtigten vom 04.09.2025. Der Einreicher erklärt, dass er auf Anfrage eine vollständige Aufschlüsselung der in den genannten Spannen zu jedem Preis verkauften Aktien bereitstellen wird.
FAQ
What did John W. Kozarich report on the Form 4 for LGND?
Were the sales by the director part of a 10b5-1 trading plan?
What price information is provided for the sales?
On what date were the transactions executed and when was the form signed?
Does the Form 4 indicate any other changes in beneficial ownership?
